Rossari Biotech Ltd Q1 FY26 Earnings Results – 3% fall in Profits

Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India. Presenting below are its Q1 FY26 earnings.

 

Q1 FY26 Earnings Summary

• Consolidated Revenue from Operations: ₹543.7 crore, up 11% year-over-year (YoY) from ₹489.7 crore in Q1 FY25.

• EBITDA: ₹67.9 crore, up 4.6% YoY; EBITDA margin at 12.5% (vs. 13.3% YoY).

• Profit After Tax (PAT): ₹33.6 crore, down 3.7% YoY from ₹34.9 crore.

• Earnings Per Share (EPS): ₹6.1 (not annualized).

• Standalone Revenue: ₹365.8 crore, up 21.6% YoY.

• Standalone PAT: ₹26.2 crore, up 7.8% YoY.

• Segment Trends: Home, Personal Care & Performance Chemicals (HPPC) segment grew 16% and was a primary growth driver, while Animal Health & Nutrition (AHN) also showed 12% YoY growth. Export business showed a slight decline versus last quarter, but remained robust yearly.

• Operational Notes: Margins softened slightly due to higher input, employee, and finance costs.

 

Key Management Commentary & Strategic Highlights

• Management described Q1 FY26 as a quarter of “steady performance,” with growth led by strong momentum in HPPC and AHN despite a challenging and evolving operating environment.

• Exports were lower sequentially but improved YoY; domestic market growth remained strong, supported by a resilient product mix and customer base expansion.

• Efficiency initiatives and product-mix optimization remain a focus to drive growth over upcoming quarters.

• Ongoing capacity expansion in personal care, agrochemicals, oil & gas, and pharma verticals is expected to improve manufacturing capabilities and supply chain agility.

• Management is optimistic for H2 FY26, citing stronger recovery expected as new capacities ramp up and demand normalizes.

• Leadership continues to target sustainable value creation, customer-led innovation, and operational excellence to support long-term growth.

 

 

Q4 FY25 Earnings Summary

• Consolidated Revenue from Operations: ₹579.6 crore, up 22.6% YoY from ₹472.7 crore.

• EBITDA: ₹69.5 crore, up 9.3% YoY; EBITDA margin at 12.0% (vs. 13.5% YoY).

• PAT: ₹34.4 crore, up 0.9% YoY from ₹34.1 crore.

• EPS: ₹6.21.

• Full FY25: Revenue at ₹2,080.3 crore (+13.7%), PAT at ₹136.4 crore (+4.4%), with margins moderately below prior year due to input price headwinds.

 

To view the company’s previous earnings, click here